Monocytes and Macrophages in Cancer: Unsuspected Roles

Gouveia-Fernandes, Sofia

doi:10.1007/978-3-030-34025-4_9

Cited by 20 publications

(11 citation statements)

References 212 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…57 In addition, monocytes are a subtypes of innate immune cells, which also play signi cant roles in anti-tumor immunity by various mechanisms, such as phagocytosis, apoptosis, and cell contact-mediated antibody-dependent cellular cytotoxicity (ADCC). 58,59 The role of CD8 + T cells and monocytes in anti-tumor immunity was consistent with our results of correlation analysis, which indicated that LUAD patients in low-risk subgroup have more CD8 + T cells and monocytes in ltration.…”

Section: Discussionsupporting

confidence: 87%

A Novel Prognostic Signature of Immune-related lncRNA Pairs in Lung Adenocarcinoma

Liu

Fan

et al. 2021

Preprint

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer, but the prognosis of LUAD patients remains unsatisfactory. Here, we retrieved the RNA-seq data of LUAD cohort from The Cancer Genome Atlas (TCGA) database and then identified differentially expressed immune-related lncRNA (DEirlncRNA) pairs between LUAD and normal controls. Based on the novel method of cyclically single pairing along with a 0-or-1 matrix, we constructed a novel prognostic signature of 8 DEirlncRNA pairs in LUAD with no dependence upon specific expression levels of lncRNAs. The prognostic model exhibited significant power in distinguishing good or poor prognosis of LUAD patients and values of the area under the curve (AUC) were all over 0.70 in 1, 3, 5 years ROC curves. Moreover, the risk model was significantly associated with clinicopathological characteristics, tumor-infiltrating immune cells, immune-related molecules and sensitivity of anti-tumor drugs. This novel signature of DEirlncRNA pairs in LUAD, which did not require specific expression levels of lncRNAs, might be used to guide the administration of patients with LUAD in clinical practice.

show abstract

Section: Discussionsupporting

confidence: 87%

A Novel Prognostic Signature of Immune-related lncRNA Pairs in Lung Adenocarcinoma

Liu

Fan

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Although monocyte is the first line of defense against cancer cells, it is known to undergo a phenotypic switch and become tumor‐supportive or immunosuppressive by cancer‐induced immunoediting 24 . Thus, the impacts of the cancer‐related monocytes on cancer are identified in all traits of carcinogenesis 24 .…”

Section: Discussionmentioning

confidence: 99%

Lymphocyte‐to‐monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy

et al. 2021

View full text Add to dashboard Cite

Background Inflammation plays critical roles at different stages of carcinogenesis and cancer progression. Several previous studies showed conflicting results for the predictive role of systemic inflammation markers in the detection of clinically significant prostate cancers (CSPCs). We aimed to determine the predictive roles of lymphocyte‐to‐monocyte (LMR) and eosinophil‐to‐lymphocyte ratios (ELR) in the detection of CSPC at standard 12‐core transrectal ultrasound‐guided prostate biopsy (12‐core‐TRUS‐Bx) using our large‐cohort database. Methods Clinical and pathological data of a total of 1740 men, who underwent initial standard 12‐core TRUS‐Bx, were analyzed. LMR and ELR were calculated from the prebiopsy complete blood count. Definitions of CSPC, LMR, and ELR were “Gleason grade group ≥2,” “the lymphocyte counts/the monocyte counts,” and “the eosinophil counts/the lymphocyte counts,” respectively. Results Median (interquartile range) of serum prostate‐specific antigen (PSA) level and prostatic volume before TRUS‐Bx were 7.59 (5.02–13.12) ng/ml and 38.2 (29.0–52.9) ml, respectively. Benign prostatic lesions, clinically insignificant prostate cancers (CIPCs), and CSPCs were detected in 1179 (67.8%), 180 (10.3%), and 381 (21.9%) patients, respectively. The patients with CSPCs had older age, a higher prevalence of diabetes mellitus or hypertension, a higher rate of digital rectal examination abnormality, higher serum PSA level, lower serum testosterone level, and lower LMR than those with benign lesions or CIPCs. However, there was no difference in ELR among the three (benign lesions, CIPCs and CSPCs). In all the patients, multivariate regression analysis showed that lower LMR was an independent predictor of CSPCs compared with ELR. In the subset of men with prostate volume ≥39.3 ml, lower LMR was an independent predictor of CSPCs compared with ELR. In the subset of men with prostate volume <39.3 ml, men with lower LMR showed the tendency of having a higher probability of CSPCs without any statistical significance on the contrary to ELR. Conclusions Our data indicate that LMR can play an independent predictive role in the detection of CSPCs at initial 12‐core‐TRUS‐Bx compared with ELR. The predictive role of the LMR appears to be significant for men with larger prostate volume rather than those with smaller prostate volume.

show abstract

“…In recent years, host immune and inflammatory responses have been considered as a marker of cancer progression and prognosis, [19][20][21][22] which can be evaluated by hematological parameters, such as monocyte-to-lymphocyte ratio (MLR) and the absolute monocyte count (AMC). Monocytes play an important role in the inflammatory response produced by tumors.…”

Section: Introductionmentioning

confidence: 99%

A Survival Prediction Nomogram for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery

Ding¹,

Liu²,

Huang³

et al. 2021

CMAR

View full text Add to dashboard Cite

Background: Neoadjuvant chemoradiotherapy (NCRT) followed by surgery is a component of the standard treatment for resectable locally advanced esophageal squamous cell carcinoma (ESCC), and the parameters for survival prediction are not clear yet. Our study aimed to construct a survival prediction nomogram for ESCC with NCRT followed by surgery. Methods: We analyzed hematological parameters and related-derivative indexes from 122 ESCC patients treated with NCRT followed by surgery. Univariate and multivariate Cox survival analyses were performed to identify independent prognostic factors to establish a nomogram and predict overall survival (OS). The predictive value of the nomogram for OS was evaluated by the concordance index (C-index), decision curve analysis (DCA), the clinical impact curve (CIC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results: The pretreatment nutritional candidate, prognostic nutrition index, inflammationrelated absolute monocyte count and TNM staging were entered into the nomogram for ESCC with NCRT followed by surgery. The C-index of the nomogram for OS was 0.790 (95% CI = 0.688-0.893), which was higher than that of TNM staging (0.681; 95% CI = 0.565-0.798, P = 0.026). The DCA, CIC, NRI, and IDI of the nomogram showed moderate improvement in predicting survival. Based on the cut point calculated according to the constructed nomogram, the high-risk group had poorer OS than that of the low-risk group (P < 0.05). Conclusion:A novel nomogram based on nutrition-and inflammation-related indicators might help predict the survival of ESCC treated with NCRT followed by surgery.

show abstract

Monocytes and Macrophages in Cancer: Unsuspected Roles

Cited by 20 publications

References 212 publications

A Novel Prognostic Signature of Immune-related lncRNA Pairs in Lung Adenocarcinoma

A Novel Prognostic Signature of Immune-related lncRNA Pairs in Lung Adenocarcinoma

Lymphocyte‐to‐monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy

A Survival Prediction Nomogram for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery

Contact Info

Product

Resources

About